A phase II study of higher dose docetaxel in androgen-independent prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 4, 2006, Pages 389-394

  Laber, Damian A ^a,b   Glisson, Shawn D ^c   Hargis, Jeffery B ^c   Kosfeld, Rodney E ^c   Goldsmith, George ^c   Cervera, Alfonso ^c   La Rocca, Renato V ^a,c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^c Kentuckiana Cancer Institute   (United States)

Author keywords

Chemotherapy; Clinical trial; Docetaxel; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ANDROGEN; CIPROFLOXACIN; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AFRICAN AMERICAN; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DEATH; DEHYDRATION; DEPRESSION; DETERIORATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HORMONE DEPENDENCE; HUMAN; INFECTION; KAPLAN MEIER METHOD; LACRIMATION; MALE; METASTASIS; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; MIDDLE AGED; PROSTATE TUMOR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS;

EID: 33746788646     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000221357.12412.b7     Document Type: Article

References (31)

1. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormoneresistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
2. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
3. Laber DA, Kloecker GH, Bhupalam L. Advances in the Management of Metastatic Androgen Independent Prostate Cancer. J Ky Med Assoc. 2006;104:67-71.
4. Ringel I, Horwitz S. Studies with RP56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst. 1988;83:288-291.
5. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol. 1999;26:14-18.
6. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 1999;26:19-23.
7. Berry W, Dakhil S, Gregurich MA, et al. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001;28:8-15.
8. Beer TM, Pierce WC, Lowe BA, et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273-1279.
9. Petrioli R, Pozzessere D, Messinese S, et al. Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy. Oncology. 2003;64:300-305.
10. Gravis G, Bladou F, Salem N, et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer. 2003;98:1627-1634.
11. Karavasilis V, Briasoulis E, Siarabi O, et al. Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy. Clin Prostate Cancer. 2003;2:46-9.
12. Tannock IF, deWit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
13. Petrylak DP, Macarthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol. 1999;17:958-967.
14. Kreis W, Budman D, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999;10:33-38.
15. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001;19:2509-2516.
16. Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003;21:123-128.
17. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
18. de WR, Kruit WH, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer. 1998;78:1342-1345.
19. Colevas AD, Posner MR. Docetaxel in head and neck cancer: a review. Am J Clin Oncol. 1998;21:482-486.
20. Aapro M. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group. Semin Oncol. 1998;25(suppl 12):7-11.
21. Dimopoulos MA, Deliveliotis C, Moulopoulos LA, et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology. 1998;52:56-60.
22. Latreille J, Gelmon KA, Hirsh V, et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest New Drugs. 1998;16:265-270.
23. Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur J Cancer. 1997;33:2167-2170.
24. Budman DR, Petroni GR, Johnson JL, et al. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol. 1997;15:3275-3279.
25. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994;5:533-537.
26. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland). World Health Organization Offset Publication No. 1979;48.
27. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
28. Bubley G, Carducci M, DAhut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clni Oncol. 1999;17:3461-3467.
29. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical practice guideline no. 9. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1994. ACHPR publication no. 94-0592.
30. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-1237.